Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction

Pierre Vladimir Ennezat (1) , Shona Cosgrove , Sylvestre Marechaux (2) , Helene Bouvaist (3) , Thierry H. Le Jemtel , Denis Vital Durand

1 Service de cardiologie
2 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517
3 Service de Cardiologie

Ivabradine is an original drug that has been approved in two indications (systolic heart failure and angina). The aim of this short review is to draw the attention of clinician prescribers to the evidence base of ivabradine. Three large randomized trials testing ivabradine versus placebo have been performed. The BEAUTIFUL and SIGNIFY trials were in fact negative in the treatment of angina while the SHIFT trial found a marginal benefit of ivabradine over placebo in the treatment of heart failure. These important results are put into perspective in order to improve the assessment of risk-cost/benefit balances when ivabradine is considered. Ideally, a further clinical trial investigating the use of ivabradine in heart failure should be carried out with optimal treatment of the patient population in order to identify the subgroup of patients who respond to ivabradine.

Domaines: Sciences du Vivant [q-bio]

Pierre Vladimir Ennezat, Shona Cosgrove, Sylvestre Marechaux, Helene Bouvaist, Thierry H. Le Jemtel, et al.. Limited role and benefit of ivabradine in the treatment of angina and heart failure with reduced ejection fraction. Acta Cardiologica, 2017, 72 (6), pp.664-668. ⟨10.1080/00015385.2017.1297627⟩. ⟨hal-03583873⟩